Braidwell »

Ultragenyx Pharmaceutical shares owned by Braidwell

Quarter-by-quarter ownership of Ultragenyx Pharmaceutical (RARE) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Ultragenyx Pharmaceutical

Tip: Access up to 7 years of quarterly data

All positions including Ultragenyx Pharmaceutical held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ultragenyx Pharmaceutical by Braidwell

Quarter filed Position value Share count Share price at filing
2025-09-30 $18M 589k 30.08

More positions owned by Braidwell

Guardant Health Debt 1.250% 2/1 (Principal)
Caris Life Sciences (CAI)
Novocure Note 11/0 (Principal)
Xenon Pharmaceuticals (XENE)
Cg Oncology (CGON)
Neurocrine Biosciences (NBIX)
Repligen Corp Note 1.000%12/1 (Principal)
Krystal Biotech (KRYS)
Nuvalent Inc-a (NUVL)
Neogenomics Note 0.250% 1/1 (Principal)
Soleno Therapeutics (SLNO)
Irhythm Technologies Note 1.500% 9/0 (Principal)
Edgewise Therapeutics (EWTX)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Inspire Med Sys (INSP)

View all positions for Braidwell

Top funds holding Ultragenyx Pharmaceutical

Vanguard Group
FMR
BlackRock
Jpmorgan Chase & Co
Sands Capital Management
State Street Corporation
Rtw Investments
Baker Bros. Advisors
Jacobs Levy Equity Management
Suvretta Capital Management
Wellington Management Company
Geode Capital Management
Deutsche Bank Aktiengesellschaft
Bnp Paribas Investment Partners
Pictet Asset Management Holding SA

View all funds holding Ultragenyx Pharmaceutical